ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Bioimpedance Analysis to Predict Clinical Outcomes of Liver Cirrhosis in a Prospective Cohort Study.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Bioimpedance analysis (BIA) is a non-invasive method for estimating body composition, which plays a role in the development of cirrhosis. We investigated if BIA measures were associated with cirrhosis complications. Methods: We analyzed data from 566 participants in a prospective cohort study of cirrhosis patients from tertiary care clinics who underwent BIA at enrollment and regular follow up (20.3% female; 47.0% non-Hispanic White, 23.1% Hispanic, 27.7% Black; 47.7% metabolic and alcohol-associated liver disease [MetALD], 30.4% metabolic dysfunction-associated steatotic liver disease [MASLD], 1.9% alcohol-associated liver disease [ALD], 9.0% active hepatitis C virus [HCV]). We performed multivariable logistic regression to assess the association of BIA measures with etiology and prevalent decompensation and Cox proportional hazards regression to assess incident decompensation and HCC. Results: After adjustment for sex and race, body fat mass was associated with 14-fold increased odds of MASLD (adjusted odds ratio [aOR] 14.10, 95% confidence interval [CI] 5.25-37.85) and decreased odds of ALD (aOR 0.73, 95% CI 0.60-0.88). Lower odds of prevalent decompensation were seen in the highest tertile of trunk lean mass (aOR 0.39, 95% CI 0.21-0.73) and left arm lean mass (aOR 0.40, 95% CI 0.21-0.75) compared with their lowest tertiles. The middle tertile of visceral fat surface area showed an inverse association with incident decompensation (adjusted hazard ratio 0.19, 95% CI 0.04-0.88). There were no significant associations between BIA measures and incident HCC. Conclusions: BIA could be used as a prognostic tool for patients with cirrhosis, supporting its incorporation into clinical workflows.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.